Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Watson Pharmaceuticals


In a report published Monday, Canaccord Genuity reiterated its Buy rating on Watson Pharmaceuticals (NYSE: WPI), and raised its price target from $90.00 to $100.00.

Canaccord Genuity noted, “Call volume on WPI has been heavy and we expect focus to remain high given the event heavy path into year-end. We've taken a deeper look at our model and upcoming catalysts, and consistent with our report Wednesday, ‘A thematic look at specialty pharma positioning amidst macro uncertainty,' continue to like the name into year-end. Post review, we leave our 2013-2015 pro forma EPS estimates unchanged, reflecting a 22% CAGR and 3-5% above consensus but with now greater confidence in upside. We take a closer look at what can take WPI higher with EPS sensitivity around potential upside using 2014 as a baseline year.”

Watson Pharmaceuticals closed on Friday at $83.90.

Latest Ratings for WPI

Jan 2013DowngradesBuyNeutral
Nov 2012MaintainsOutperform
Nov 2012UpgradesNeutralOverweight

View More Analyst Ratings for WPI
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (WPI)

View Comments and Join the Discussion!

Latest Ratings

ADBECleveland ResearchInitiates Coverage On283.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Koesterich Rates Switzerland Short-Term Underweight

UPDATE: Bank of America Initiates Textainer Group at Neutral on Balanced Outlook